about
Mild cognitive impairment (MCI) in medical practice: a critical review of the concept and new diagnostic procedure. Report of the MCI Working Group of the European Consortium on Alzheimer's DiseaseMild cognitive impairment and its management in older peopleCerebrospinal fluid and blood biomarkers in Alzheimer's diseaseExploring Biomarkers for Alzheimer's DiseaseThe Alzheimer's disease neuroimaging initiative.Dkk-3 is elevated in CSF and plasma of Alzheimer's disease patientsBiomarkers in translational research of Alzheimer's diseaseNanoparticle-based detection in cerebral spinal fluid of a soluble pathogenic biomarker for Alzheimer's diseaseAnalysis of chiral amino acids in cerebrospinal fluid samples linked to different stages of Alzheimer disease.Alterations of matrix metalloproteinases in the healthy elderly with increased risk of prodromal Alzheimer's disease.Biomarkers: mining the biofluid proteome.Identifying and validating biomarkers for Alzheimer's disease.T1rho MRI and CSF biomarkers in diagnosis of Alzheimer's disease.CSF biomarkers for Alzheimer's disease: current utility and potential future use.Two Blood Monocytic Biomarkers (CCL15 and p21) Combined with the Mini-Mental State Examination Discriminate Alzheimer's Disease Patients from Healthy SubjectsClinical trials in mild cognitive impairment: lessons for the future.Cognitive reserve and Aβ1-42 in mild cognitive impairment (Argentina-Alzheimer's Disease Neuroimaging Initiative).Cerebrospinal fluid biomarkers for Alzheimer's disease: the role of apolipoprotein E genotype, age, and sex.Sphingomyelin SM(d18:1/18:0) is significantly enhanced in cerebrospinal fluid samples dichotomized by pathological amyloid-β42, tau, and phospho-tau-181 levels.The ratio of phosphatidylcholines to lysophosphatidylcholines in plasma differentiates healthy controls from patients with Alzheimer's disease and mild cognitive impairmentUsing Pittsburgh Compound B for in vivo PET imaging of fibrillar amyloid-beta.Early diagnostics and therapeutics for Alzheimer's disease--how early can we get there?Peptides and proteins in plasma and cerebrospinal fluid as biomarkers for the prediction, diagnosis, and monitoring of therapeutic efficacy of Alzheimer's disease.Cerebrospinal fluid tau cleaved by caspase-6 reflects brain levels and cognition in aging and Alzheimer diseaseThe Memory and Aging Telephone Screen: development and preliminary validation.The effects of normal aging and ApoE genotype on the levels of CSF biomarkers for Alzheimer's disease.Cerebrospinal fluid biomarkers of Alzheimer's disease in healthy elderly.Biomarkers in Sporadic and Familial Alzheimer's Disease.The developing landscape of diagnostic and prognostic biomarkers for spinal cord injury in cerebrospinal fluid and blood.Cerebral Hemodynamics in Mild Cognitive Impairment: A Systematic Review.Cerebrospinal Fluid Biomarkers of Alzheimer's Disease Correlate With Electroencephalography Parameters Assessed by Exact Low-Resolution Electromagnetic Tomography (eLORETA).Liquid chromatography/tandem mass spectrometry characterization of oxidized amyloid beta peptides as potential biomarkers of Alzheimer's disease.CSF biomarkers in the evaluation of idiopathic normal pressure hydrocephalus.On-line capillary electrophoresis derivatization method for high sensitivity analysis of ubiquitin in filtered cerebrospinal fluid.Low cerebrospinal fluid sulfatide predicts progression of white matter lesions: The LADIS study.Candidate genes, pathways and mechanisms for alcoholism: an expanded convergent functional genomics approach.White matter diffusivity predicts memory in patients with subjective and mild cognitive impairment and normal CSF total tau levels.MRI evidence of bilateral hippocampal sclerosis in amnestic mild cognitive impairment.CSF biomarkers correlate with cerebral blood flow on SPECT in healthy elderly.Plasma lipids metabolism in mild cognitive impairment and Alzheimer's disease.
P2860
Q24678457-67546C93-F963-49EE-BFED-9A4AC0FD3CC3Q26822601-F926F442-6B96-4639-AF91-59613958B8D0Q27023758-37019EFD-E1A6-45B2-8823-671CF1403807Q28079218-4EC8E629-A3A8-466F-8E89-40DB539FE3F1Q31030939-BBA95EC0-01D5-4A8C-93E0-222FE5353D85Q33448926-184F5229-DE53-4DFF-9614-32B14166C3C7Q33556189-E457F592-3EA1-4C64-81FB-EFD832E0B53FQ33850134-55681C2E-220D-4588-9291-4FE293A10AB7Q34044474-B03385B0-190F-4E39-91D8-71F5AA66B914Q34058311-288DF785-1D94-4047-8A28-BCB6E98EBB6BQ34389937-0A92AA87-90B9-4349-A904-CD8EF79F8CBBQ34468961-07C5ADDE-AA97-4217-82E4-D8D5A0034229Q35221966-E518C357-DF6E-47BA-9DDA-5CE9DE38B9AEQ35600993-E8D785C0-2EE0-4009-B258-83E5CDC624A9Q35607653-63188112-63CB-431C-8313-C704D3383CBDQ36142255-65BF7DD6-9FBA-4FD6-9D8E-09BC3F8B1E79Q36160452-E56D3C1C-5539-47FB-8B98-015424AA0BF0Q36399100-81C26119-B5A7-4F58-BC1C-CAFE03B37FA8Q36424510-A0554676-3FC2-471B-9617-1E797BB754D5Q36428387-CD928AC1-DC34-4CB9-8B3F-001D585168BEQ36526176-179F5178-5C71-4D84-B1AC-E7CD8B6BF0FCQ36607324-913E4D24-3FFB-4AE6-9B70-B8E5EE9D33AEQ37068847-9D372CC0-3F42-492C-9EFB-62AC602FD8D2Q37184051-1ECC92EE-4150-4A3F-9D21-ADCEF835D375Q37267578-136F37C1-D6AE-4C5F-BC0A-A10F60EA1DF1Q37415302-CF3E8457-3B30-4AE9-A35C-560E42CC369AQ37524486-00E43EF8-B352-45F8-A7BA-167E3466A624Q38592041-F05D0794-F0B8-437D-9EFB-0BE96E87882BQ39044367-2CD63E48-C367-401A-9324-D5EDF5A26BE1Q39410816-561B14F6-17E1-47E8-B20D-8B7B81E0A615Q39497929-C4D20126-2A2C-4040-8D37-F4FAFC511667Q46938051-7FC2E790-1064-4CE3-8CA5-205D50844034Q46961181-1030E3F8-252A-4810-9564-77C9DB619C63Q48001827-95D3AEDF-487B-4CBA-BFA6-B3E15F138C74Q48398819-FD0D9CDE-9C9A-4E45-A95E-66EF1024D2F4Q48399038-AAA9975B-139B-4E3F-AFB8-3D4E77EEBBA9Q48431936-367FAA17-B378-4801-83BD-C1153440A42CQ48438638-E4E04B81-289E-4626-B234-8F0E46786E28Q48464443-A1B99D11-29C1-4B54-9F6E-EBDC7EA3DCFBQ50041775-7D9E553D-CFF3-4B07-A2D8-743DA89A4A38
P2860
description
2004 nî lūn-bûn
@nan
2004 թուականի Սեպտեմբերին հրատարակուած գիտական յօդուած
@hyw
2004 թվականի սեպտեմբերին հրատարակված գիտական հոդված
@hy
2004年の論文
@ja
2004年論文
@yue
2004年論文
@zh-hant
2004年論文
@zh-hk
2004年論文
@zh-mo
2004年論文
@zh-tw
2004年论文
@wuu
name
CSF biomarkers for mild cognitive impairment.
@ast
CSF biomarkers for mild cognitive impairment.
@en
type
label
CSF biomarkers for mild cognitive impairment.
@ast
CSF biomarkers for mild cognitive impairment.
@en
prefLabel
CSF biomarkers for mild cognitive impairment.
@ast
CSF biomarkers for mild cognitive impairment.
@en
P2860
P1476
CSF biomarkers for mild cognitive impairment.
@en
P2093
P2860
P304
P356
10.1111/J.1365-2796.2004.01368.X
P407
P577
2004-09-01T00:00:00Z